A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer

Trial Profile

A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Ipatasertib (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ECLIPSE
  • Most Recent Events

    • 12 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top